Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk

The burden of diabetes mellitus is growing dramatically, mainly through its atherosclerotic cardiovascular impact.1., 2. On the contrast, diabetes is also associated with cancer development and the mechanism underlying this phenomenon is complicated.3., 4., 5. Recently, novel antidiabetic agent with sodium-glucose cotransporter-2 (SGLT2) inhibitors was introduced and several pluripotent effect was proposed.6., 7. In this regard, to identify the role of pharmacologic intervention in incident cancer among diabetic individuals is truly novel and interesting and clearly of importance for health care delivery and quality control efforts.8., 9. Therefore, this study was conducted for evaluation of the relation between SGLT2 Inhibitors and risk of incident cancer among patients with diabetes with large size of the database examined, and the clinical importance of the question examined.

留言 (0)

沒有登入
gif